Prikaz osnovnih podataka o dokumentu

dc.creatorVuković, Rade
dc.creatorZeljković, Aleksandra
dc.creatorBufan, Biljana
dc.creatorSpasojević-Kalimanovska, Vesna
dc.creatorMilenković, Tatjana
dc.creatorVekić, Jelena
dc.date.accessioned2020-02-27T11:54:39Z
dc.date.available2020-02-27T11:54:39Z
dc.date.issued2019
dc.identifier.issn1664-2392
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/3536
dc.description.abstractHashimoto autoimmune thyroiditis (AIT) is the most common cause of acquired hypothyroidism in the pediatric population. Development of AIT is mediated mainly by cellular immune response directed toward thyroid autoantigens, leading to inflammation and impaired function of thyroid gland. Both thyroid dysfunction and inflammation affect the metabolism of plasma lipoproteins. The alterations in lipid profile worsen with the advancement of hypothyroidism, ranging from discrete changes in euthyroid AIT patients, to atherogenic dyslipidemia in the overt hypothyroidism. In this review, characteristics of dyslipidemia in pediatric AIT patients, and the consequences in respect to the risk for cardiovascular disease (CVD) development are discussed. Additionally, benefit of L-thyroxine treatment on serum lipid profile in pediatric AIT patients is addressed. Finally, potential usefulness of novel lipid biomarkers, such as proprotein convertase subtilisin/kexin type 9 (PCSK9), non-cholesterol sterols, low-density lipoprotein particle size and number, and high-density lipoprotein structure and functionality in AIT patients is also covered. Further longitudinal studies are needed in order to elucidate the long-term cardiovascular outcomes of dyslipidemia in pediatric patients with Hashimoto AIT.en
dc.description.abstractarticle
dc.publisherFrontiers Media S.A.
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceFrontiers in Endocrinology
dc.subjectchildren
dc.subjectdyslipidemia
dc.subjectHashimoto autoimmune thyroiditis
dc.subjectL-thyroxine treatment
dc.subjectnovel lipid biomarkers
dc.titleHashimoto Thyroiditis and Dyslipidemia in Childhood: A Reviewen
dc.rights.licenseBY
dcterms.abstractЗељковић, Aлександра; Векић, Јелена; Вуковић, Раде; Спасојевић-Калимановска, Весна; Буфан, Биљана; Миленковић, Татјана;
dc.citation.volume10
dc.identifier.wos000504261900001
dc.identifier.doi10.3389/fendo.2019.00868
dc.identifier.scopus2-s2.0-85077333076
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs/bitstream/id/7579/bitstream_7579.pdf
dc.type.versionpublishedVersion


Dokumenti

Thumbnail

Ovaj dokument se pojavljuje u sledećim kolekcijama

Prikaz osnovnih podataka o dokumentu